原位异种移植小鼠SCID模型中恶性人U87胶质母细胞瘤的病毒疗法

Virotherapy of the Malignant U87 Human Glioblastoma in the Orthotopic Xenotransplantation Mouse SCID Model.

作者信息

Shchelkunov S N, Razumov I A, Kolosova I V, Romashchenko A V, Zavjalov E L

机构信息

Institute of Cytology and Genetics, Siberian Branch, Russian Academy of Sciences, Novosibirsk, 630090, Russia.

Vector State Research Center of Virology and Biotechnology, Koltsovo, Novosibirsk oblast, 633159, Russia.

出版信息

Dokl Biochem Biophys. 2018 Jan;478(1):30-33. doi: 10.1134/S1607672918010088. Epub 2018 Mar 14.

DOI:10.1134/S1607672918010088

PMID:29536305

Abstract

The possibility of glioblastoma virotherapy at intravenous injection of the LIVP-GFP recombinant virus was studied in experimental model of orthotopic xenotransplantation of human glioblastoma cell line U87 to SCID laboratory mice. The LIVP-GFP recombinant virus deficient for thymidine kinase exhibited a significantly greater oncolytic capacity than the original LIVP virus, and an intravenous injection of LIVP-GFP at the early stages of tumorigenesis in mouse brain in most cases resulted in the lysis of the tumor.

摘要

在人胶质母细胞瘤细胞系U87原位异种移植到SCID实验小鼠的实验模型中，研究了静脉注射LIVP-GFP重组病毒进行胶质母细胞瘤病毒疗法的可能性。缺乏胸苷激酶的LIVP-GFP重组病毒表现出比原始LIVP病毒显著更强的溶瘤能力，并且在小鼠脑肿瘤发生的早期阶段静脉注射LIVP-GFP在大多数情况下导致肿瘤溶解。